Skip to main content
Caplight Logo









DEMECAN

DEMECAN

Private
EbersbachHealthcare & Life Scienceshttps://www.demecan.de/

Last Round

VC Round

Aug 7, 2024

Est. Valuation

$109.2M

Total Funding Raised

$7.63M

Company Overview

DEMECAN is a pharmaceuticals and biotechnology company that produces, imports, and supplies medical cannabis in Germany.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain, Compliance

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

medical cannabiscannabis cultivationEU-GMP certifiedpharmaceutical cannabismedical marijuanacannabis extractscannabis flowerscannabinoid therapypharmaceutical supply chaincannabis wholesaleBfArMcannabis industry

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DEMECAN Comparables

Compare DEMECAN with similar companies based on industry and business-model similarity.

DEMECAN comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Semdor Pharma Group
84%
SOMAÍ Pharmaceuticals
83%
enua Pharma GmbH
83%

DEMECAN Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundAug 7, 2024
VC RoundDec 19, 2022
VC RoundApr 15, 2021
Series A ExtensionMay 19, 2020
Series AOct 1, 2019

Key People

Founding team and executive leadership

Roman Faber

CFO - Power Of Attorney (Prokurist)

Executive Team

Sebastian Müllers

Chief Operating Officer (COO), Chief Operating Officer, COO

Executive Team

DEMECAN Investors

Notable investors and investment history

DEMECAN investors
InvestorRounds
Mittelständische Beteiligungsgesellschaft SachsenVC Round
Futury CapitalVC Round
b2ventureVC Round, Series A
Future Capital AGSeries A
Trog Hawley CapitalVC Round
ENEXISVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 26, 2026

    Expanding cultivation at Ebersbach site to boost domestic production capacity.

  • Dec 19, 2022

    $16M raised from b2venture, ENEXIS, and others.

DEMECAN Filings

Explore SEC and related filing metadata, where available.

DEMECAN filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DEMECAN's valuation, stock price, and market status.

Is DEMECAN a public or private company?

DEMECAN is a private company.

What is the current stock price of DEMECAN?

DEMECAN is a private company with no public stock price. No recent secondary market data is available.

How much is DEMECAN worth (valuation)?

DEMECAN's valuation is estimated at $109.2M based on funding round data.

Can I buy DEMECAN stock?

DEMECAN shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DEMECAN's last funding round?

DEMECAN's most recent funding round was VC Round on August 7, 2024.

Who are the main investors in DEMECAN?

Key investors in DEMECAN include Futury Capital, b2venture, Trog Hawley Capital.

Will DEMECAN IPO soon?

No public IPO plans have been announced for DEMECAN.

How can I track DEMECAN secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DEMECAN's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEbersbach
Employee Range54
Year Founded2017
Last FundingAug 7, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?